Fresenius Medical Care stock gains after JPMorgan reiterates Underweight rating

Published on 09/15/2026 at 14:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius Medical Care stock traded around EUR 39.56 on Xetra on September 15, 2026, after European medtech sentiment and a JPMorgan Underweight rating shaped the picture. The shares recently closed nearly 3 percent higher in a weak European market.

Moderner Dialyseraum mit Hämodialysegeräten und Patientenliegen bei Tageslicht — Ein fotorealistisches Bild eines modernen Dialyseraums mit mehreren Hämodialysegeräten und Patientenliegen in Reihe, ruhigem Tageslicht durch große Fenster – typisch für die Behandlungszentren von Fresenius Medical Care AG (ISIN DE0005785802), Illustration mit AI erstellt.

Fresenius Medical Care stock (ISIN DE0005785802) traded at about EUR 39.56 on Xetra on September 15, 2026, up roughly 2.9 percent from the prior close in intraday indications, in a continuation of the nearly 3 percent gain it posted the previous trading day in Europe as broader markets weakened.

Analyst stance and recent price reaction

According to Finanznachrichten on September 14, 2026, JPMorgan has reiterated its Underweight rating on Fresenius Medical Care, reflecting a cautious view on European medtech names despite the recent share price recovery in the sector.

As Finanznachrichten reported on September 14, 2026, European stocks generally closed weaker, but Fresenius Medical Care ended the session nearly 3 percent higher, standing out against the negative trend in several major continental indices.

Chart indications and short-term momentum

Per a chart-based overview from finanzen.net on September 15, 2026, Fresenius Medical Care shares around EUR 39 to EUR 40 are trading in the lower half of their recent range, with several analyst ratings clustered between Underweight, Underperform and Equal Weight, alongside at least one Buy recommendation from DZ Bank during August 2026.

In the same finanzen.net analyst overview dated September 15, 2026, JPMorgan maintained its Underweight stance from September 9, 2026, while Jefferies kept the stock at Underperform and Barclays at Equal Weight, indicating that most international houses see limited upside at the current level despite the short-term price gains.

Market data signal for investors

Based on intraday indications from German trading venues on September 15, 2026, Fresenius Medical Care shares were quoted around EUR 39.56 on Xetra, with a daily increase of approximately 2.9 percent versus the previous close and a bid-ask range just under EUR 40; in Hamburg trading, quotes around EUR 39.45 in the early morning similarly pointed to a gain of a little more than 3 percent compared with the prior session.